Immunome

immunome.com

Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates, radioligand therapies and a gamma secretase inhibitor. It aims to improve outcomes for cancer patients by advancing treatments for significant unmet medical needs.

Facts

HQ
Bothell, Washington, US
Sectors
Biotechnology Research
Employees
283
Founders
Clay Siegall

Is this your organization? Claim it

Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics

Clay Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food andDrug Administration (FDA) in 2011. Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997…

People

Online

Questions about Immunome

What is Immunome?

immunome.com

Who are the people behind Immunome?

Seattle Flow lists Clay Siegall (Executive, President and CEO) at Immunome.

Where is Immunome based?

Immunome is headquartered in Bothell, Washington, US.

How many people work at Immunome?

Immunome has 283 employees.